New hope for painful skin condition: brensocatib enters phase 2b trial
Disease control
Terminated
This study tests whether brensocatib can reduce painful lumps and abscesses in people with moderate to severe hidradenitis suppurativa (HS). About 214 adults will receive either brensocatib or a placebo for 16 weeks. The goal is to see if the drug improves skin lesions and overal…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC